Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.
Bibliographical notePublisher Copyright:
© The Author 2016.
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases